fourD: Placebo data from the 4D study
In aallignol/etm: Empirical Transition Matrix

Description Usage Format Source References Examples

Data from the placebo group of the 4D study. This study aimed at comparing atorvastatin to placebo for patients with type 2 diabetes and receiving hemodialysis in terms of cariovascular events. The primary endpoint was a composite of death from cardiac causes, stroke and non-fatal myocardial infarction. Competing event was death from other causes.

1	data(fourD)

A data frame with 636 observations on the following 7 variables.

id: Patients' id number
sex: Patients' gender
age: Patients' age
medication: Character vector indicating treatment affiliation. Here only equal to "Placebo"
status: Status at the end of the follow-up. 1 for the event of interest, 2 for death from other causes and 0 for censored observations
time: Survival time
treated: Numeric vector indicated whether patients are treated or not. Here always equal to zero

Wanner, C., Krane, V., Maerz, W., Olschewski, M., Mann, J., Ruf, G., Ritz, E (2005). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine, 353(3), 238–248.

Allignol, A., Schumacher, M., Wanner, C., Dreschler, C. and Beyersmann, J. (2010). Understanding competing risks: a simulation point of view. Research report.